Active Biotech
ISIN: SE0001137985 | Ticker: ACTI | LEI: 549300OJ44CLMRU8YE43
Country: Sweden
Active Biotech develops pharmaceutical products within medical areas where the immune system is of significant importance, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.
Active Biotech has its base in Lund, Sweden and was formed in 1998 as a spin-off from Pharmacia & Upjohn. The share is listed and traded on Nasdaq Stockholm (Small Cap). The Company has core competence in cancer and inflammatory diseases and a competent team with extensive experience in drug development from early to late stage clinical development.
1998
HeadquartersScheelevägen 22, 22363 Lund – Sweden
| Line item in (sek) | 02.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|
| Assets | N/A | 32,155,000.00 | N/A | 56,804,000.00 | N/A | 51,005,000.00 |
| Noncurrent Assets | N/A | 1,871,000.00 | N/A | 946,000.00 | N/A | 6,885,000.00 |
| Noncurrent Receivables | N/A | 1,000.00 | N/A | 1,000.00 | N/A | 376,000.00 |
| Current Assets | N/A | 30,284,000.00 | N/A | 55,858,000.00 | N/A | 44,120,000.00 |
| Current Trade Receivables | N/A | 284,000.00 | N/A | 0.00 | N/A | N/A |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | N/A | N/A | 1,534,000.00 | N/A | 1,377,000.00 |
| Current Tax Assets Current | N/A | 739,000.00 | N/A | 739,000.00 | N/A | 600,000.00 |
| Cash and cash equivalents | 59,681,000.00 | 26,213,000.00 | 26,213,000.00 | 53,134,000.00 | 53,134,000.00 | 41,796,000.00 |
| Equity And Liabilities | N/A | 32,155,000.00 | N/A | 56,804,000.00 | N/A | 51,005,000.00 |
| Equity | 53,783,000.00 | 22,113,000.00 | 22,113,000.00 | 46,674,000.00 | 46,674,000.00 | 34,511,000.00 |
| Issued Capital | N/A | 750,000.00 | N/A | 1,126,000.00 | N/A | 1,368,000.00 |
| Retained Earnings | N/A | -3,290,505,000.00 | N/A | -3,340,047,000.00 | N/A | -3,397,729,000.00 |
| Additional Paidin Capital | N/A | 3,311,868,000.00 | N/A | 3,385,595,000.00 | N/A | 3,430,872,000.00 |
| Liabilities | N/A | 10,042,000.00 | N/A | 10,130,000.00 | N/A | 16,494,000.00 |
| Noncurrent Liabilities | N/A | 689,000.00 | N/A | 226,000.00 | N/A | 4,432,000.00 |
| Current Liabilities | N/A | 9,353,000.00 | N/A | 9,904,000.00 | N/A | 12,062,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 2,852,000.00 | N/A | 2,761,000.00 | N/A | 3,528,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | N/A | 6,128,000.00 | N/A | 6,692,000.00 |
| Other Current Payables | N/A | 219,000.00 | N/A | 255,000.00 | N/A | 236,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 6,725,000.00 | 0.00 | 0.00 |
| Profit Loss From Operating Activities | -32,306,000.00 | -49,782,000.00 | -57,886,000.00 |
| Finance Income | 215,000.00 | 15,000.00 | 49,000.00 |
| Finance Costs | 154,000.00 | 58,000.00 | 535,000.00 |
| Profit Loss Before Tax | -32,245,000.00 | -49,825,000.00 | -58,372,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -32,245,000.00 | -49,825,000.00 | -58,372,000.00 |
| Profit Loss Attributable To Owners Of Parent | -32,245,000.00 | -49,825,000.00 | -58,372,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Line item in (sek) | 01.01.2021 | 02.01.2020 | 01.01.2022 | 02.01.2021 | 01.01.2023 | 02.01.2022 |
|---|---|---|---|---|---|---|
| Profit (loss) | -32,245,000.00 | N/A | -49,825,000.00 | N/A | -58,372,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | 1,896,000.00 | N/A | 1,562,000.00 | N/A | 2,185,000.00 | N/A |
| Adjustments For Reconcile Profit Loss | 1,896,000.00 | N/A | 1,562,000.00 | N/A | 2,185,000.00 | N/A |
| Cash Flows From Used In Operating Activities | -32,216,000.00 | N/A | -46,166,000.00 | N/A | -54,850,000.00 | N/A |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | N/A | 0.00 | N/A | 245,000.00 | N/A |
| Cash Flows From Used In Investing Activities | N/A | N/A | 0.00 | N/A | -245,000.00 | N/A |
| Proceeds From Issuing Shares | 0.00 | N/A | 76,249,000.00 | N/A | 46,832,000.00 | N/A |
| Payments Of Lease Liabilities Classified As Financing Activities | 1,252,000.00 | N/A | 1,015,000.00 | N/A | 1,762,000.00 | N/A |
| Cash Flows From Used In Financing Activities | -1,252,000.00 | N/A | 73,087,000.00 | N/A | 43,757,000.00 | N/A |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 0.00 | N/A | 0.00 | N/A | 0.00 | N/A |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | -33,468,000.00 | N/A | 26,921,000.00 | N/A | -11,338,000.00 | N/A |
| Cash and cash equivalents | 26,213,000.00 | 59,681,000.00 | 53,134,000.00 | 26,213,000.00 | 41,796,000.00 | 53,134,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 05.09.22 | Aleksandar Danilovski | Other | Buy | SEK 26,672.00 |
| 22.04.22 | Helen Tuvesson Andersson | Other | Buy | SEK 3,102.86 |
| 21.04.22 | Helen Tuvesson Andersson | Other | Buy | SEK 41,767.60 |
| 17.06.21 | Aleksandar Danilovski | Other | Buy | SEK 60,000.00 |
| 01.06.21 | Michael Shalmi | Other | Buy | SEK 259,437.50 |
| 27.04.21 | Helen Tuvesson Andersson | Other | Buy | SEK 16,657.60 |
| 27.04.21 | Helena Eriksson | Other | Buy | SEK 14,460.00 |
| 27.04.21 | Helen Tuvesson Andersson | Other | Buy | SEK 1,665.60 |
| 26.04.21 | Helen Tuvesson Andersson | Other | Buy | SEK 13,961.58 |
| 26.04.21 | Peter Thelin | Other | Other | SEK 0.00 |
SE0001137985
LEI549300OJ44CLMRU8YE43
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.